AVR (ASX) Answers from Wayne

Originally posted by Willbo ↑

Hi guys I’ve spoken to Wayne about the last 4c
Answers in red.
Let’s trust this guy he knows what he is talking about !!
Plus he takes time out to respond to questions

With June -December 2017 will that be Fy2017 or will that be a one off?and there be no 1hFy2018 Until July 2018?
As we moved from financial to calendar reporting (predominately to make our financials more digestible to US funds, we had to close out half year 2017 (June to December) and overlap that with the financial year. As of now we are on calendar year and so the reporting (1st HALF) will be reflected as you have stated in July 2018.

With 2m extra expected this coming Quarter in staff cost why is there such a big jump?
Not to be a martyr about it but our staff costs are still relatively low considering the size of the undertaking (we need perspective here as I am a fiscal conservative generally). We still have less heads than we need which means a lot of the team is still (happily) putting in many more hours than they signed up for.

The costs however do reflect new staff, some close out costs (termination obligations ) , and 2017 bonuses. I appreciate a lot of our shareholders struggle with the issue of bonuses , but they are a necessary part of the global healthcare business(and we are contractually obligated to pay them) - and an important aspect of the reward system (and retention process where needed). Although the share price is vexing to say the least , the actual company performance was very good during 2017 (profit up , costs down, revenues up) and as such in most case is well deserved. Keeping in mind we cant run the company without great people - this in turn will drive the share price. The bonus structure is performance based (as such some people didnt earn theirs) but for the most part the company did perform well against its targets. I think for the moment we are at critical mass however as every 1 of our team = 3 of the competitors !

If we get a Vax and a TAVR deal will there be a new guidance for our 20 earnings for 2020?
I expect that if one or both of these come through I will adjust the guidance upwards.

Are we far off getting approval in MENA for 3D? Close -
I believe there may be some initial orders to some markets from next month.

Are we still on track for the 17.5m in ADAPT sales this FY? (4.3m each quarter) seems a big jump from the 2.1 for the December quarter.
Agree- on face value its a decent step up , but the variables that come into play include new reps coming from very specific backgrounds (we couldn’t attract this type of rep 18 months ago), implementation of an industry leading campaign, increasing publications and data , improved company image and credibility (driven by data as well as TAVR which is giving us much better profile in the big institutions). There are always known knowns, and known unknowns, (which we have factored in). Portfolio expansion will also play a role later in the year as well.We will hit the target.

Any news on the tenders for infusions side of the business we Quoted?
No news yet - we are in play but the cycles are proving to be very long with regards to decision making at the hospital level. I am confident the team will succeed in areas where we can compete.

Is it okay if I put your responses in the hot copper forum? Yes

Expand

Wilbo: Are we still on track for the 17.5m in ADAPT sales this FY?

WP: "....We will hit the target."

I am very much looking forward to that statement coming true.

No.	Vol.	Price($)
1	60	$17.88

No.

Vol.

Price($)

$17.88

Price($)	Vol.	No.
$18.05	554	1

Price($)

Vol.

No.

$18.05

554

No.	Vol.	Price($)
1	60	17.880
1	47	17.870
1	619	17.860
1	37	17.650
2	700	17.550

No.

Vol.

Price($)

17.880

17.870

619

17.860

17.650

700

17.550

Price($)	Vol.	No.
18.050	554	1
18.100	1000	1
18.200	343	2
18.300	150	1
18.500	43	1

Price($)

Vol.

No.

18.050

554

18.100

1000

18.200

343

18.300

150

18.500

(20min delay)
Last $17.97		Change -0.235(1.29%)		Mkt cap ! $345.3M

Open	High	Low	Value	Volume
$18.09	$18.09	$17.88	$1.182K	66

Wilbo: Are we still on track for the 17.5m in ADAPT sales this...

Legacy shares jump on discovery of multiple epithermal veins at Bauloora JV

Greentech finds lithium trend across 5.5 km at WA's Kobe South

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

American West does it again at Storm with visually identified thick copper hits at Cyclone, Lightning Ridge

PYC commences new study on drug for eye condition Retinitis Pigmentosa type 11

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Wilbo: Are we still on track for the 17.5m in ADAPT sales this...

Top Stories

Legacy shares jump on discovery of multiple epithermal veins at Bauloora JV

Greentech finds lithium trend across 5.5 km at WA's Kobe South

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

American West does it again at Storm with visually identified thick copper hits at Cyclone, Lightning Ridge

PYC commences new study on drug for eye condition Retinitis Pigmentosa type 11

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News